产品
编 号：F423918
分子式：C15H14BrN
分子量：288.18
分子式：C15H14BrN
分子量：288.18
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 677746-25-7
产品详情
生物活性：
K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease.
体内研究：
K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo.Animal Model:5xFAD mice with cerebral Aβ amyloidosis
Dosage:100 μM
Administration:Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks
Result:Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to50% of the mock-treated level.
体外研究：
K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO.K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons.
K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease.
体内研究：
K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo.Animal Model:5xFAD mice with cerebral Aβ amyloidosis
Dosage:100 μM
Administration:Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks
Result:Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to50% of the mock-treated level.
体外研究：
K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO.K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备